Breakdown | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 181.09B | 150.84B | 140.04B | 129.55B | 130.88B |
Gross Profit | 90.58B | 68.82B | 68.28B | 66.47B | 74.93B |
EBITDA | 57.25B | 34.82B | 31.53B | 31.57B | 28.00B |
Net Income | 32.43B | 16.71B | 16.48B | 18.84B | 15.33B |
Balance Sheet | |||||
Total Assets | 464.38B | 428.25B | 396.81B | 350.98B | 319.06B |
Cash, Cash Equivalents and Short-Term Investments | 73.23B | 78.08B | 94.75B | 67.55B | 61.31B |
Total Debt | 70.34B | 79.69B | 79.69B | 49.69B | 52.85B |
Total Liabilities | 134.27B | 132.89B | 124.57B | 92.87B | 85.89B |
Stockholders Equity | 300.53B | 270.80B | 252.04B | 239.77B | 217.78B |
Cash Flow | |||||
Free Cash Flow | 6.23B | -14.45B | 1.74B | 10.73B | 6.69B |
Operating Cash Flow | 33.82B | 5.61B | 16.45B | 21.31B | 16.10B |
Investing Cash Flow | -24.97B | -19.35B | -15.49B | -9.11B | -7.35B |
Financing Cash Flow | -19.87B | -4.42B | 24.42B | -8.18B | -10.43B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | $270.91B | 10.47 | 9.09% | 3.84% | 14.60% | 8.97% | |
51 Neutral | $7.86B | -0.26 | -41.41% | 2.22% | 22.87% | -2.01% | |
― | $4.11B | 32.84 | 10.94% | ― | ― | ― | |
― | $2.09B | 16.13 | 7.24% | 2.47% | ― | ― | |
― | $1.20B | 15.02 | 5.93% | 2.34% | ― | ― | |
― | $1.21B | 28.51 | 4.52% | ― | ― | ― | |
77 Outperform | ¥79.96B | 8.47 | 3.40% | 9.83% | 86.18% |
Tsumura & Co reported a decrease in its consolidated financial results for the first quarter ending June 30, 2025, with net sales slightly declining by 1.4% and significant drops in operating profit and ordinary profit by 27.0% and 56.2%, respectively. The company’s projections for the fiscal year ending March 31, 2026, indicate a modest increase in net sales by 3.8%, but a continued decline in profits, reflecting challenges in maintaining profitability amidst market conditions.
The most recent analyst rating on (JP:4540) stock is a Buy with a Yen6000.00 price target. To see the full list of analyst forecasts on Tsumura & Co stock, see the JP:4540 Stock Forecast page.
Tsumura & Co. has announced that its subsidiary, Tsumura China Inc., will acquire a 51% stake in Shanghai Hongqiao Traditional Chinese Drug Pieces Co., Ltd. This strategic acquisition aims to expand Tsumura’s crude drug platform in China, leveraging Hongqiao’s sales capabilities and Tsumura’s expertise in personalized medicine and quality assurance. The move is expected to enhance product quality and increase convenience for patients, aligning with Tsumura’s vision to contribute to the health of the Chinese population.
The most recent analyst rating on (JP:4540) stock is a Buy with a Yen6000.00 price target. To see the full list of analyst forecasts on Tsumura & Co stock, see the JP:4540 Stock Forecast page.
Tsumura & Co. has concluded its share repurchase program, acquiring 530,400 shares at a total cost of 1,971,140,100 yen. This move, completed on the Tokyo Stock Exchange, marks the end of a strategic initiative resolved by the Board of Directors to enhance shareholder value and optimize capital structure.
The most recent analyst rating on (JP:4540) stock is a Buy with a Yen6000.00 price target. To see the full list of analyst forecasts on Tsumura & Co stock, see the JP:4540 Stock Forecast page.